Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To interested investors:see my sticky post.
Excellent post!
You forgot SeeThruEquities,a reliable analyst firm. This firm gives AMBS a target of $45/share or a +400 million dollar market cap
AMBS:The diagnostic division is worth between 300m and 1billion dollar. If the CEO can manage a spin off (it is his intention) of the diagnostic from the therapeutic division alone, with dividend shares in the diagnostic division for the current shareholders, share price will go north 5 dollar alone (which is a MC of 50 million dollar). Why? By doing a spin off, a takeover for the diagnostic division will be much easier to do. Also the diagnostic division is generating revenues and will increase to do so. By owing a stake (like the current shareholders) in the diagnotic division the therapeutic division will also be generating revenues and if a buyout happens they will get the buyout money as well, or they can sell their stake on a moment the company (therapeutic division) needs the money.
The diagnostic division is worth between 300m and 1billion dollar. If the CEO can manage a spin off of the diagnostic from the therapeutic division alone, with dividend shares in the diagnostic division for the current shareholders, share price will go north 5 dollar alone (which is a MC of 50 million dollar). Why? By doing a spin off, a takeover for the diagnostic division will be much easier to do. Also the diagnostic division is generating revenues and will increase to do so. By owing a stake (like the current shareholders) in the diagnotic division the therapeutic division will also be generating revenues and if a buyout happens they will get the buyout money as well, or they can sell their stake on a moment the company (therapeutic division) needs the money.
AMBS:company with a possible game changing technology
AMBS: target $45/share,wants to uplist to Nasdaq soon
Here is the analyst report from SeethruEquity:
NEW YORK, NY / ACCESSWIRE / July 24, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Amarantus BioScience Holdings, Inc. (AMBS) with a Price Target of $45.34.
The report is available here: AMBS Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
Based in California, Amarantus BioScience Holdings (AMBSD) is a biotechnology company developing treatments and diagnostics neurology and orphan indications. As a biotechnology company, AMBS is developing treatments for wound healing, Parkinson's disease Levodopa-Induced Dyskinesia (PD-LID), Adult Attention Deficit Hyperactivity Disorder (ADHD), and Retinitis Pigmentosa, as well as developing better diagnostics to test for Alzheimer's disease and Multiple Sclerosis.
"AMBS has an impressive portfolio of product candidates across its diagnostic and therapeutic divisions. In particular, AMBS just recently announced that it has completed the acquisition of Cutanogen Corporation from Lonza Walkersville, Inc. a subsidiary of Lonza Group Ltd. Cutanogen has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute or ESS, a tissue-engineered skin replacement prepared from a patient's own skin cells. ESS has the potential to become a revolutionary treatment for severe burns and management believes that the path to approval for ESS could be rapid, potentially as quick as two years with market potential of $500 million," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $45.34 per share."
Additional highlights from the report are as follows:
Strong Portfolio of Lead Products in Therapeutic Division: Engineered Skin Substitute (ESS), Eltoprazine and MANF
AMBS's therapeutic division's lead product candidates are ESS, Eltoprazine and Mesencephalic-astrocyte-derived neurotrophic factor (MANF). ESS is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. ESS has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting. ESS is also being developed with support from the Armed Forces Institute for Regenerative Medicine (AFIRM). The AFIRM grant was initially worth $3mm with $0.75mm remaining and was awarded to support the IND and initial clinical studies. An IND with the US FDA is active, ESS has received orphan drug designation and a Phase 2 study is expected to open in 3Q15. Key catalysts in this program are around acceleration of the regulatory timeline as well as clinical data expected to come on a per patient basis given the special nature of the trial being initiated at a US military clinical site.
Eltoprazine is a small molecule 5HT1a/1b partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Adult ADHD, and Alzheimer's Aggression. Eltoprazine has been evaluated in over 600 human subjects to date, and has shown a strong and well established safety profile, as well as initial proof of concept data funded by the Michael J. Fox Foundation and published in the journal BRAIN. AMBS is expecting to have Phase 2b program clinical data in the first half of 2016 for Eltoprazine treatment in PD-LID.
MANF is believed to have broad potential because it is a naturally occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease. AMBS is the front-runner and primary holder of intellectual property around MANF, and is focusing on the development of MANF-based protein therapeutics. MANF has demonstrated efficacy as a disease-modifying treatment in various animal models, including retinitis pigmentosa, Parkinson's disease, cardiac ischemia and stroke. AMBS has also received European Union Orphan Drug Destination for MANF for the treatment of retinitis pigmentosa (RP). Amarantus expects to initiate human clinical studies in the second half of 2016 in RP.
Neuro-diagnostic division seeks to enhance the industry standard
AMBS's diagnostics division's lead developments are the MSPrecise(R) and the LymPro Test(R). MSPrecise(R) is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. MSPrecise(R) utilizes next-generation sequencing to measure DNA mutations found in rearranged immunoglobulin genes in immune cells initially isolated from cerebrospinal fluid.The Lymphocyte Proliferation Test, LymPro, is a diagnostic blood test for Alzheimer's disease that works by evaluating the cell surface marker CD69 on peripheral blood lymphocytes following a mitogenic stimulation. If the CD69 is not up-regulated when measured, it means there is a dysfunctional cellular machinery division process, and Alzheimer's is more likely to be present. To help fuel the advancement of their Therapeutics pipeline, management has indicated they are evaluating strategic exit opportunities for their diagnostics division including potentially selling off the division, spinning off the division into its own company, or licensing the technologies to a third party.
PhenoGuard(TM) shows strong potential to further Drug Division
PhenoGuard(TM) is a proprietary discovery technology that played an essential role to developing MANF. Going forward, management believes that this drug discovery platform can be used to discover other, similar neurotrophic factors. The PhenoGuard(TM) technology currently consists of 88 cell lines, and management intends to expand the number of such cell lines through additional research.
Please review important disclosures on our website at www.seethruequity.com.
http://finance.yahoo.com/news/seethruequity-initiates-coverage-amarantus-bioscience-130000691.html
AMBS: target $45/share,wants to uplist to Nasdaq soon
Here is the analys report from SeethruEquity:
NEW YORK, NY / ACCESSWIRE / July 24, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Amarantus BioScience Holdings, Inc. (AMBS) with a Price Target of $45.34.
The report is available here: AMBS Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
Based in California, Amarantus BioScience Holdings (AMBSD) is a biotechnology company developing treatments and diagnostics neurology and orphan indications. As a biotechnology company, AMBS is developing treatments for wound healing, Parkinson's disease Levodopa-Induced Dyskinesia (PD-LID), Adult Attention Deficit Hyperactivity Disorder (ADHD), and Retinitis Pigmentosa, as well as developing better diagnostics to test for Alzheimer's disease and Multiple Sclerosis.
"AMBS has an impressive portfolio of product candidates across its diagnostic and therapeutic divisions. In particular, AMBS just recently announced that it has completed the acquisition of Cutanogen Corporation from Lonza Walkersville, Inc. a subsidiary of Lonza Group Ltd. Cutanogen has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute or ESS, a tissue-engineered skin replacement prepared from a patient's own skin cells. ESS has the potential to become a revolutionary treatment for severe burns and management believes that the path to approval for ESS could be rapid, potentially as quick as two years with market potential of $500 million," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $45.34 per share."
Additional highlights from the report are as follows:
Strong Portfolio of Lead Products in Therapeutic Division: Engineered Skin Substitute (ESS), Eltoprazine and MANF
AMBS's therapeutic division's lead product candidates are ESS, Eltoprazine and Mesencephalic-astrocyte-derived neurotrophic factor (MANF). ESS is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. ESS has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting. ESS is also being developed with support from the Armed Forces Institute for Regenerative Medicine (AFIRM). The AFIRM grant was initially worth $3mm with $0.75mm remaining and was awarded to support the IND and initial clinical studies. An IND with the US FDA is active, ESS has received orphan drug designation and a Phase 2 study is expected to open in 3Q15. Key catalysts in this program are around acceleration of the regulatory timeline as well as clinical data expected to come on a per patient basis given the special nature of the trial being initiated at a US military clinical site.
Eltoprazine is a small molecule 5HT1a/1b partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Adult ADHD, and Alzheimer's Aggression. Eltoprazine has been evaluated in over 600 human subjects to date, and has shown a strong and well established safety profile, as well as initial proof of concept data funded by the Michael J. Fox Foundation and published in the journal BRAIN. AMBS is expecting to have Phase 2b program clinical data in the first half of 2016 for Eltoprazine treatment in PD-LID.
MANF is believed to have broad potential because it is a naturally occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease. AMBS is the front-runner and primary holder of intellectual property around MANF, and is focusing on the development of MANF-based protein therapeutics. MANF has demonstrated efficacy as a disease-modifying treatment in various animal models, including retinitis pigmentosa, Parkinson's disease, cardiac ischemia and stroke. AMBS has also received European Union Orphan Drug Destination for MANF for the treatment of retinitis pigmentosa (RP). Amarantus expects to initiate human clinical studies in the second half of 2016 in RP.
Neuro-diagnostic division seeks to enhance the industry standard
AMBS's diagnostics division's lead developments are the MSPrecise(R) and the LymPro Test(R). MSPrecise(R) is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. MSPrecise(R) utilizes next-generation sequencing to measure DNA mutations found in rearranged immunoglobulin genes in immune cells initially isolated from cerebrospinal fluid.The Lymphocyte Proliferation Test, LymPro, is a diagnostic blood test for Alzheimer's disease that works by evaluating the cell surface marker CD69 on peripheral blood lymphocytes following a mitogenic stimulation. If the CD69 is not up-regulated when measured, it means there is a dysfunctional cellular machinery division process, and Alzheimer's is more likely to be present. To help fuel the advancement of their Therapeutics pipeline, management has indicated they are evaluating strategic exit opportunities for their diagnostics division including potentially selling off the division, spinning off the division into its own company, or licensing the technologies to a third party.
PhenoGuard(TM) shows strong potential to further Drug Division
PhenoGuard(TM) is a proprietary discovery technology that played an essential role to developing MANF. Going forward, management believes that this drug discovery platform can be used to discover other, similar neurotrophic factors. The PhenoGuard(TM) technology currently consists of 88 cell lines, and management intends to expand the number of such cell lines through additional research.
Please review important disclosures on our website at www.seethruequity.com.
http://finance.yahoo.com/news/seethruequity-initiates-coverage-amarantus-bioscience-130000691.html
I give him credit till Dec2016 until I make an evaluation. I want to see a Nasdaq uplisting, positive phase 2B results and at least one partnership with Johnson&Johnson, Genzyme, GSK, Roche or Abott. If he doesn't succeed in doing this before the end of 2016 the CEO should be fired. But for now I do give him credit.
They will partner (already using the labarotories of Johnson & Johnson for free),spin off the diagnostic from the therapeutic division (current shareholders will be paid a dividend to get a Free stake in the therapeutic division and uplist at the same time). This company (pipeline, IP, ...) is worth so much more than the minimum bid price of $1/share or a MC of 9 million dollar to comply with Nasdaq regulations.
Und dann... Market Cap $400m like SeeThruequities analysts say.
Das is richtig. Wir mussen etwas warten.
New$$$:Amarantus Submits Orphan Drug Designation Application to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia
http://finance.yahoo.com/news/amarantus-submits-orphan-drug-designation-131500070.html
Never buy biotech companies with a junior pipeline. Now is the time to buy. They have a more mature pipeline, ready to uplist, did a very big RS, and are covered by a reputable analyst company like SeeThruequities
Let's wait one more year to make an evaluation. I want to see a Nasdaq uplisting, positive phase 2B results and at least one partnership with Johnson&Johnson, Genzyme, GSK, Roche or Abott. If he doesn't succeed in doing this before the end of 2016 the CEO should be fired. But for now I give him credit.
It is OTC and not yet Nasdaq. So when the Biotech index rises, it will not affect AMBS. Once they will have moved to Nasdaq it changes. But it takes time... In my humble opinion they want to do all at once: do a spin-off between the therapeutic and diagnostic division, with current shareholders getting a dividend in shares of the diagnostic division while their shares of the therapeutic division won't change AND uplist to Nasdaq. But that takes time, lawyers, legal discussions, ... In my humble opinion: I am bullish and think that over two years, when some products are in phase 3, the seethruequity target of +400 million dollar market cap, (currently $45/share target, but the number of OS will likely increase) will be easily reached.
Therefore they want to uplist to Nasdaq. This increases the credibility and banks will be more willing to give loans. This is a big buying opportunity now IMO
AMBS: Blue what do you think about this company?
A simple question, a simple answer, a non-depressed outlook
Do you think their therapeutic and diagnostic pipeline and intellectual property is worth more than 9million dollars, which is the market cap when the share price is at $1 -which is the minimum bid price to go on Nasdaq? I think so, moreover Seethruequity -which is a reputable analyst firm- thinks so too and values AMBS a market cap of more than $400 million.
http://finance.yahoo.com/news/seethruequity-initiates-coverage-amarantus-bioscience-130000691.html
Spin off of the therapeutische division (the diagnostic division is worth at least $300 million, but more like somewhere between $1-2 billion),partnerships,...$2m/month cash burn is not that much by the way for a biotech company.
AMBS: Target $45/share accoring to Seethruequity
http://finance.yahoo.com/news/seethruequity-initiates-coverage-amarantus-bioscience-130000691.html
A simple question, a simple answer, a non-depressed outlook
Do you think their therapeutic and diagnostic pipeline and intellectual property is worth more than 9million dollars, which is the market cap when the share price is at $1 -which is the minimum bid price to go on Nasdaq? I think so, moreover Seethruequity -which is a reputable analyst firm- thinks so too and values AMBS a market cap of more than $400 million.
http://finance.yahoo.com/news/seethruequity-initiates-coverage-amarantus-bioscience-130000691.html
Yes, can you give me some info about that please?
They've much liabilitites and below 1M cash. But I have also read about warrants, can someone elaborate me on this? Is there a ground floor on warrant exercise and how much money is the company planning to make upon this?
I see the company has almost no cash left. Are there warrants being exercised to increase the cash position and at what level are they exercised?
The company needs its' current cash to pay off the cut in personnel and the closure of the Canadian office. It is easy for this fund to exercise below .05 and probably below .02 because the demand for a possible 1:100 reverse split is not encouraging at all for investors. Also the next financial report will now be an even bigger disaster than the previous one.
There was a fund which didn't agree with this. This fund hold 10 procent of the warrants. And this fund is currently starting to exercise the warrants. You should expect that this fund will play Wall Street style, with no mercy and therefore they will bring the share price down to .01 or maybe lower IMO. Therefore the company will need to do a 1:100 reverse split to comply with Nasdaq regulations because they will at least need one more financing deal (dilution) to have enough cash until ZopTec phase 3 results will be published. Normally they would have had enough cash, but the closure of the Canadian office and the cut in personnel is very expensive on a one time basis.
I really cannot understand how they screwed this up!!!!
I deleted my sticky.At this moment I cannot express my opinion to people anymore to buy shares of this company. It is probably better to buy after November 16 or later.
They will also need to do another round of financing to compensate the closure of their office in Canada and to compensate the 'firing' costs of the Canadian employees. Therefore they need to stay on Nasdaq to get sufficient financing otherwise they have to file Chapter 11.
I still remain very bullish about their pipeline, it is great. But they financially screwed it up and they will bear the consequences for a period.
Time to buy more. This share price is so cheap.
ZoptEC P3 for endometrial cancer will be successfull IMO,here is why:
This article from a German magazine
Ergomeds Co-Development Partner Aeterna Zentaris receives recommendation-the Data Safety Monitoring Board to continue Phase III ZoptEC trial in advanced endometrial cancer-
Recommendation follows the second interim analysis of the Phase III clinical trial with doxorubicin in advanced endometrial Zoptarelin (endometrial cancer)
Offering, a profitable company based in the United Kingdom (UK), the specialized services for the pharmaceutical industry and the development of new drugs;: 14 October 2015 - Guildford, UK Ergomed plc (2EM GR: ERGO LN, Xetra AIM Ergomed) dedicated, is pleased to announce can, that their co-development partner Aeterna Zentaris (NASDAQ: AEZS) (TSX: AEZ) a recommendation of the Data Safety Monitoring Board (DSMB) to continue their pivotal ZoptEC ("Zoptarelin doxorubicin in Endometrial Cancer ") Phase III clinical trial with doxorubicin Zoptarelin received in women with advanced, recurrent or metastatic endometrial cancer.
Dr. Miroslav Reljanovic, Chief Executive Officer of Ergomed, commented: "We have completed patient enrollment ahead of schedule and the trial remains as planned, we are delighted with the recommendation of the DSMB to continue the ZoptEC Phase III study.. We are convinced that Zoptarelin doxorubicin has the potential to treat advanced, recurrent endometrial cancer and the study's lead with Aeterna Zentaris with utmost commitment continue. " bfontana yahoofinance
"Two things: 1. Enrollment ahead of schedule 2. Open label study. Oncologists talk to eachother "Dr X., how are you, I am happy to see you again here at the congress. Are you also particpating to this open label trial for endometrial cancer? Not yet? You should really do that, I have seen ZoptEC really works for most of my patients with some very compelling results. THE STATEMENT enrollment ahead of schedule is very, very bullish" annickawaechter yahoofinance
MORE INFORMATION ABOUT AETERNA ZENTARIS
The company has sufficient cash until February2017
Btw final phase 3 results for ZopTec in endometrial cancer will be released by the end of 2016.
From the conference call last August:
'Finally, I’d like to address our current financial position in the recent pressure on our stock price. During the first quarter of this year, we made the decision to raise a significant amount of capital to support us through the next 18 months of the implementation of our strategy.'
Also: restructuring so more financial power, and closing of the Quebec office, so AEZS is now officially a US based company with an extra office in Germany:
David A. Dodd, Chairman, President and Chief Executive Officer of the Company commented, "After a comprehensive review, the Company's Board reached the decision to take these actions, including the closure of our Quebec City office by the end of December, making all associates based there redundant. We will transfer many of the functions now performed in our Quebec City office to other personnel and we will strengthen our financial team with the addition of new finance and accounting personnel in our Charleston, South Carolina office. A comprehensive search for a Chief Financial Officer and the other finance and accounting personnel required is underway. Mr. Keith Santorelli, our Vice President, Finance, will succeed Mr. Turpin as our Chief Accounting Officer, with responsibility for all internal and external financial reporting on an interim basis while the Company conducts an external search for a permanent CFO. We appreciate Keith's leadership and commitment to ensuring a smooth transition in our finance and accounting function."
"I would like to thank our colleagues in Quebec City for their contributions to the Company. This decision was difficult but necessary. With these actions, we intend to create value for our shareholders by
Enhancing shareholder and investment community confidence and support
Improving our operating effectiveness and efficiency and
Increasing the strength of our management team.
We will provide information regarding the financial implications of these actions during our discussion of our third quarter results."
FURTHER:
The company has TWO products in phase 3:
ZopTec for endometrial cancer with final evaluation by the DSMB on safety and efficacy early October. It has the potential to become the first FDA approved treatment for endometrial cancer.
Macrilen for the diagnosis of Adult Growth Hormone Deficiency. It has the potential to become the golden standard in diagnosing AGHD.
The company also has TWO products which have met their primary endpoint without safety concerns:
ZopTec for ovarian cancer and heavily pretreated prostate cancer.
More:
DSMB-safety/efficacy evaluation: positive evaluation for ZopTec phase 3 trial for endometrial cancer: AEZS may continue the trial.
Price estimate on this excellent news:
$.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes
1.23=consensus price target of 6 analysts
More: some other important notes on their pipeline:
1.An oral vaccin partnered with a German company which will pay for the enterie development, pays an upfront fee, milestones and royalties once commercialized
2 ERK-inhibitors, partnered for 12 months (pre-)clinical testing with a German company, with an option for development and commercialization after 12months testing. Upfront fee, milestones and royalties.
Wall Street: emotions versus fundamentals
There are 6 analysts covering AEZS with a mean price target of $1.23/share
If the CEO of AEZS meets the Estrogel goals he will have reached all his 2015 goals for the company, so I would like to congratulate him with that.
There has been restructuring in personnel and in working place, I love that. Less costs, is more time to reach additional endpoints, so more far than February 2017 (during the August CC he said that the company has sufficient cash to continue operations for 18 months).
Dennis Turpin, CFO is fired, b/c he did a bad job with the warrant deal. Currently the share price is suffering under the warrant deal and if you act by EMOTIONS AND NOT BY FUNDAMENTALS, by HEART AND NOT BY BRAIN, you sell and you will regret it.
Personally, my target for this company is $2.5 billion dollars. When it reached that evaluation, I will consider selling my shares.
Copied from yahoofinance, author: annickawaechter
Yes,me too.Holding till 2.5billion dollar Market Cap.
Wall Street: emotions versus fundamentals
There are 6 analysts covering AEZS with a mean price target of $1.23/share
If the CEO of AEZS meets the Estrogel goals he will have reached all his 2015 goals for the company, so I would like to congratulate him with that.
There has been restructuring in personnel and in working place, I love that. Less costs, is more time to reach additional endpoints, so more far than February 2017 (during the August CC he said that the company has sufficient cash to continue operations for 18 months).
Dennis Turpin, CFO is fired, b/c he did a bad job with the warrant deal. Currently the share price is suffering under the warrant deal and if you act by EMOTIONS AND NOT BY FUNDAMENTALS, by HEART AND NOT BY BRAIN, you sell and you will regret it.
Personally, my target for this company is $2.5 billion dollars. When it reached that evaluation, I will consider selling my shares.
Copied from yahoofinance, author: annickawaechter
During the shareholder meeting there has been voted that in the worst case scenario, even when an appeal at the Nasdaq hearing panel is negative and a pps of$1/share hasn't been reached, a max RS 1:8 is allowed. Thus, stop posting nonsense on this board.
There is a reason for the$1.23/share consensus analyst price target. It is called VALUE BASED ON FUNDAMENTALS and at the end fundamentals always win, even on Wall Street.
Ok, you are talking about 2013. Hahahaha
Not a failure, the request for a confirmatory trial. You're a typical basher. 6analyst have a $1.23/share price target. That must hurt you, doesn't it?
Possible near term catalysts:estrogel sales expected to double this year (see company presentation), possible partnership announcements (I expect a European partnership for ZopTec since they want to do it themeselves in the US), acquisition of an extra commercial product, ...
Thanks for the extra publicity for my sticky post. You bash my post, because it is close to the perfect summary.
The company has sufficient cash until February2017
Btw final phase 3 results for ZopTec in endometrial cancer will be released by the end of 2016.
From the conference call last August:
'Finally, I’d like to address our current financial position in the recent pressure on our stock price. During the first quarter of this year, we made the decision to raise a significant amount of capital to support us through the next 18 months of the implementation of our strategy.'
Also: restructuring so more financial power, and closing of the Quebec office, so AEZS is now officially a US based company with an extra office in Germany:
David A. Dodd, Chairman, President and Chief Executive Officer of the Company commented, "After a comprehensive review, the Company's Board reached the decision to take these actions, including the closure of our Quebec City office by the end of December, making all associates based there redundant. We will transfer many of the functions now performed in our Quebec City office to other personnel and we will strengthen our financial team with the addition of new finance and accounting personnel in our Charleston, South Carolina office. A comprehensive search for a Chief Financial Officer and the other finance and accounting personnel required is underway. Mr. Keith Santorelli, our Vice President, Finance, will succeed Mr. Turpin as our Chief Accounting Officer, with responsibility for all internal and external financial reporting on an interim basis while the Company conducts an external search for a permanent CFO. We appreciate Keith's leadership and commitment to ensuring a smooth transition in our finance and accounting function."
"I would like to thank our colleagues in Quebec City for their contributions to the Company. This decision was difficult but necessary. With these actions, we intend to create value for our shareholders by
Enhancing shareholder and investment community confidence and support
Improving our operating effectiveness and efficiency and
Increasing the strength of our management team.
We will provide information regarding the financial implications of these actions during our discussion of our third quarter results."
FURTHER:
The company has TWO products in phase 3:
ZopTec for endometrial cancer with final evaluation by the DSMB on safety and efficacy early October. It has the potential to become the first FDA approved treatment for endometrial cancer.
Macrilen for the diagnosis of Adult Growth Hormone Deficiency. It has the potential to become the golden standard in diagnosing AGHD.
The company also has TWO products which have met their primary endpoint without safety concerns:
ZopTec for ovarian cancer and heavily pretreated prostate cancer.
More:
DSMB-safety/efficacy evaluation: positive evaluation for ZopTec phase 3 trial for endometrial cancer: AEZS may continue the trial.
Price estimate on this excellent news:
$.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes
1.23=consensus price target of 6 analysts
More: some other important notes on their pipeline:
1.An oral vaccin partnered with a German company which will pay for the enterie development, pays an upfront fee, milestones and royalties once commercialized
2 ERK-inhibitors, partnered for 12 months (pre-)clinical testing with a German company, with an option for development and commercialization after 12months testing. Upfront fee, milestones and royalties.
Price estimate after todays' positive DSMB evaluation:
$.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes
1.23=consensus price target of 5 analysts